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SObjective: The objective of the present study was to evaluate whether the outcomes of lung transplantation in
patients aged 70 years or older have changed after implementation of the lung allocation score in May 2005.
Methods: Patients aged 70 years or older undergoing primary lung transplantation from 1995 to 2009 were iden-
tified from the United Network for Organ Sharing registry. The primary stratification was the pre-lung allocation
score era versus lung allocation score era. Risk-adjusted multivariate Cox regression and Kaplan-Meier analyses
were conducted to evaluate the effect of age 70 years or older on 1-year post-transplant mortality compared with
a reference cohort of patients aged 60 to 69 years.
Results: Of the overall 15,726 adult lung transplantation patients in the study period, 225 (1.4%) were 70 years
old or older and 4634 (29.5%) were 60 to 69 years old. The patients aged 70 years or older were a larger cohort of
overall lung transplantation patients in the lung allocation score era compared with before the lung allocation
score era (3.1% vs 0.3%, P<.001). In the risk-adjusted Cox analysis, age 70 years or older was a significant
risk factor for 1-year post-lung transplantation mortality in the pre-lung allocation score era (hazard ratio, 2.00;
95% confidence interval, 1.10-3.62, P ¼ .02) but not in the lung allocation score era (hazard ratio, 1.02; 95%
confidence interval, 0.71-1.46; P ¼ .92). Similarly, Kaplan-Meier 1-year survival was significantly reduced in
patients 70 years old or older versus 60 to 69 years old in the pre-lung allocation score era (56.7% vs 76.3%,
P ¼ .006) but not in the lung allocation score era (79.0% vs 80.0%, P ¼ .72).
Conclusions: Recipients aged 70 years or older were a larger proportion of overall lung transplantation patients
after implementation of the lung allocation score. Although associated with significantly increased post-lung
transplantation mortality in the pre-lung allocation score era, age 70 years or older is currently associated
with outcomes comparable to those of patients aged 60 to 69 years. Therefore, age 70 years or older should
not serve as an absolute contraindication to lung transplantation in the lung allocation score era. (J Thorac Car-
diovasc Surg 2012;144:1133-8)With an aging population in the United States, the number
of patients with end-stage lung disease will undoubtedly
continue to increase. This again brings into question the
long debated issue of what the upper age limit should be
for recipients of lung transplantation (LTx). A consensus re-
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The Journal of Thoracic and CarHeart and Lung Transplantation recommended that recipi-
ent age older than 65 years should serve as a relative contra-
indication to LTx.1 This recommendation was based on
International Society for Heart and Lung Transplantation
registry data demonstrating reduced survival in this elderly
cohort.2 It is unknown whether the implementation of the
lung allocation score (LAS) in May 2005 has been met
with any changes in outcomes after LTx in elderly recipi-
ents. In the present study, we evaluated the trends and out-
comes of LTx in recipients aged 70 years or older in the
United States.PATIENTS AND METHODS
Data Source
The United Network for Organ Sharing (UNOS) data set was used for
the present study. The UNOS registry collects patient-level data on all
transplantations performed in the United States. The Johns Hopkins
University School of Medicine approved our study.
Study Population
All adult patients (age>17 years) undergoing LTx between January 1,
1995, and December 31, 2009 were initially identified in the UNOS data
set. Patients undergoing multivisceral transplantation, including heart–
lung transplantation, were excluded. Redo lung transplants were also
excluded from the analysis.diovascular Surgery c Volume 144, Number 5 1133
Abbreviations and Acronyms
LAS ¼ lung allocation score
LTx ¼ lung transplantation
UNOS ¼ United Network for Organ Sharing
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STrends in LTx in Elderly Recipients
To examine nationwide trends, we stratified the recipients into 3 age
groups: 18 to 59 years, 60 to 69 years, and 70 years old or older. The abso-
lute number of recipients within each of these age cohorts was then plotted
for each year during the study period. The trends were then evaluated by
calculating the correlation coefficients (r) and the associated P values.
We also compared the trends in key baseline characteristics of elderly
recipients. Moreover, the recipient, donor, and transplant variables for re-
cipients aged 70 years or older were compared between those who under-
went transplantation in the pre-LAS era versus the LAS era. These included
the following recipient variables: age, gender, race, weight, height, body
mass index, etiology of lung disease, recent infection, dialysis while on
thewait list, serum creatinine, serum bilirubin, serum cytomegalovirus pos-
itivity, bridging with extracorporeal membrane oxygenation, mechanical
ventilation before transplantation, intensive care unit before transplanta-
tion, diabetes mellitus, hypertension, previous malignancy, and blood
transfusion while on the wait list. Donor variables that were compared in-
cluded age, gender, race, weight, height, body mass index, serum cytomeg-
alovirus positivity, cigarette use, diabetes mellitus, terminal creatinine,
hypertension, inotrope use, and mechanism of death. The transplant vari-
ables included transplant type (single versus bilateral LTx), days on the
wait list, ischemic time, and center volume. Pairing data between the recip-
ient and donor included gender matching, race matching, blood type
matching, donor/recipient body mass index ratio, donor/recipient weight
ratio, donor/recipient height ratio, human leukocyte antigen matching,
and cytomegalovirus status matching.
Risk-Adjusted Cox Regression Analysis
Multivariate Cox regression models were constructed to examine the
risk-adjusted effect of recipient age 70 years or older on 1-year all-cause
mortality after LTx. The reference cohorts in these analyses were recipients
aged 60 to 69 years. Risk adjustment was performed for the recipient, do-
nor, and transplant variables that were associated with 1-year mortality on
exploratory univariate analysis (P< .2) and had less than 20% missing
data. All the variables listed previously were tested in this exploratory anal-
ysis for potential inclusion in the multivariate models. Significant interac-
tions between covariates were thoroughly tested.
Kaplan-Meier Survival Analysis
Kaplan-Meier survival curves were also constructed. These curves were
stratified according to age cohort (age 60-69 years vs age 70 years) and
era (pre-LAS era vs LAS era). The log-rank test was used to compare
the survival curves between the age groups within each era.
Statistical Analysis
The categorical data are presented as the number and percentage and
were compared using the chi-square test or Fisher’s exact test. Continuous
data are presented as the mean  standard deviation and were compared
using the Student t test. All statistical analyses were performed using
STATA, software version 11 (StataCorp, College Station, Tex).RESULTS
Study Cohort
A total of 16,823 adult patients underwent LTx from
1995 to 2009 in the UNOS data set. Of these, 562 were1134 The Journal of Thoracic and Cardiovascular Surre-do LTx, 495 were heart–lung transplants, and 40 were
other types of multivisceral transplants. After excluding
these cases, 15,726 adult first-time, single-organ LTx pa-
tients were included in the study. Of these, 225 (1.4%)
were 70 years old or older and 4634 (29.5%) were 60-69
years old.
Trends in LTx in Elderly Recipients
Several significant trends were observed with regard to
recipient age during the study period. The proportion of
adult LTx recipients aged 18 to 59 years decreased signif-
icantly from 85.0% in 1995 to 52.5% in 2009 (P<.001;
Figure 1). During the same period, the proportion of recip-
ients aged 60 to 69 years increased from 14.8% to 43.0%
and the proportion of recipients aged 70 years or older in-
creased from 0.3% to 4.5% (P< .001). When stratified
according to the implementation of the LAS, the propor-
tion of LTx recipients who were 70 years or older in-
creased from 0.3% (n ¼ 30 of 9,338) in the pre-LAS
era to 3.1% (n ¼ 195 of 6391) in the LAS era (P<.001).
Baseline Characteristics
Also, significant trends were seen when comparing the
baseline characteristics of recipients aged 70 years or older
in the pre-LAS versus the LAS era. Moreover, septuagenar-
ian recipients in the LAS era were older (Table 1). Themean
serum creatinine level in the LAS group was significantly
lower than in the pre-LAS cohort, although no patients in
either septuagenarian cohort underwent dialysis while on
the wait list. Similar to previous data examining the effect
of the LAS for all LTx patients, elderly LTx patients in
our study in the LAS era had shorter wait list times and
a greater proportion were patients with idiopathic pulmo-
nary fibrosis with fewer having chronic obstructive pulmo-
nary disease. The mean LAS in the septuagenarian LTx
recipients in the modern cohort was 47.2  16.0.
The donors for septuagenarian recipients were well-
matched between eras (Table 2). The recipient–donor pair-
ing data were also comparable. Centers performing LTx in
recipients aged 70 years or older had significantly greater
volumes in the LAS era than in the pre-LAS era, performing
on average 9 more LTx annually.
Risk-Adjusted Cox Regression Analysis
On univariate Cox regression analysis, recipients aged
70 years or older were more than twice as likely to die
within 1 year of LTx as recipients aged 60 to 69 years in
the pre-LAS era (hazard ratio, 2.13; 95% confidence inter-
val, 1.23-3.70; P ¼ .007). In the LAS era, age 70 years or
older was not a significant risk factor for 1-year mortality
on univariate analysis (hazard ratio, 1.06; 95% confidence
interval, 0.77-1.47; P ¼ .72). Similar trends were observed
after risk adjustment for significant recipient, donor, and
transplant variables in the pre-LAS versus LAS eras.gery c November 2012
FIGURE 1. Trends in lung transplantation (LTx) recipient age during the study period.
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SMoreover, in the pre-LAS era, the risk-adjusted hazard ra-
tio for 1-year mortality in those aged 70 years or older
compared with those aged 60 to 69 years was 2.00 (95%
confidence interval, 1.10-3.62), a statistically significant
difference (P ¼ .02; Table 3). Conversely, age 70 years
or older did not exert an independent effect on 1-year mor-
tality in risk-adjusted analysis in the LAS era (hazard ratio,
1.02; 95% confidence interval, 0.71-1.46; P ¼ .92).TABLE 2. Baseline donor, transplant, and recipient-donor matching
characteristics in recipients aged 70 years or older, stratified by era
Characteristic
Pre-LAS
era (n ¼ 30)
LAS
era (n ¼ 195)
P
value
DonorKaplan-Meier Survival Analysis
Kaplan-Meier survival analysis revealed the same trends
as observed in the Cox regression analysis. In the pre-LAS
era, the 1-year survival for patients aged 60 to 69 years was
76.3%, significantly greater than the 56.7% observed for
patients aged 70 years or older (log-rank P ¼ .006;
Figure 2). After implementation of the LAS, however, the
1-year survival for recipients aged 60 to 69 years versusTABLE 1. Baseline recipient characteristics in recipients aged 70
years or older, stratified by era
Recipient characteristic
Before LAS
era (n ¼ 30)
LAS
era (n ¼ 195)
P
value
Age (y) 71.1  1.6 72.0  2.2 <.001
Female gender 5/30 (16.7%) 39/195 (20.0%) .67
White race 29/30 (96.7%) 179/195 (92.3%) .38
Diagnosis .04
IPF 18/30 (60.0%) 145/195 (74.4%)
COPD 12/30 (40.0%) 40/195 (20.5%)
Other 0/30 (0.0%) 10/195 (5.1%)
Bridging with ECMO 0/30 (0.0%) 2/193 (1.0%) .58
Mechanical ventilation 0/30 (0.0%) 14/195 (7.2%) .13
Serum cytomegalovirus
positive
15/30 (50.0%) 120/195 (61.5%) .23
Serum creatinine (mg/dL) 1.03  0.37 0.91  0.23 .01
LAS, Lung allocation score; IPF, idiopathic pulmonary fibrosis; COPD, chronic
obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation.
The Journal of Thoracic and Carrecipients aged 70 years or older was comparable (80.0%
vs 79.0%; log-rank P ¼ .72).DISCUSSION
In the present study, we reviewed the trends and out-
comes of LTx in 225 recipients aged 70 years or older.
We found that the proportion of LTx recipients who are el-
derly has increased significantly during the past 15 years in
the United States. Also, several key changes have occurred
in the characteristics of septuagenarian patients undergoing
LTx with the introduction of the LAS. These include anAge (y) 36.2  15.5 35.1  14.9 .73
Female gender 5/30 (16.7%) 39/195 (20.0%) .67
White race 21/30 (70.0%) 105/195 (53.9%) .10
Mechanism of death .42
Trauma 17/30 (56.7%) 86/195 (44.1%)
Cerebrovascular 10/30 (33.3%) 79/195 (40.5%)
Other 3/30 (10.0%) 30/195 (15.4%)
Serum cytomegalovirus
positive
17/30 (56.7%) 126/195 (64.6%) .40
LTx
Bilateral LTx 3/30 (10.0%) 43/195 (22.1%) .13
Wait list duration (d) 165.1  237.9 76.3  128.5 .002
Annual center volume 24.5  15.6 33.6  19.8 .02
Ischemic time (h) 4.3  1.9 4.6  1.4 .48
Recipient–donor matching
Gender matched 22/30 (73.3%) 140/195 (71.8%) .86
Race matched 20/30 (66.7%) 107/195 (54.9%) .23
Cytomegalovirus matched 16/30 (53.3%) 103/195 (52.8%) .96
Donor/recipient BMI ratio 1.04  0.21 1.00  0.27 .49
LAS, Lung allocation score; LTx, lung transplantation; BMI, body mass index.
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TABLE 3. Risk-adjusted multivariate analysis for 1-year mortality
Recipient age (y) 1-y Mortality P value
60-69 —
Pre-LAS era* Reference
LAS eray Reference
70
Pre-LAS era* 2.00 (1.10-3.62) .02
LAS eray 1.02 (0.71-1.46) .92
Data presented as hazard ratio (95% confidence interval). LAS, Lung allocation score;
LTx, lung transplantation; ICU, intensive care unit; ECMO, extracorporeal membrane
oxygenation. *Risk-adjusted for significant predictors of mortality in pre-LAS era:
serum creatinine, serum bilirubin, year of transplantation, wait list duration, race, me-
chanical ventilation before LTx, diabetes mellitus, ICU before LTx, etiology of lung
disease, serum cytomegalovirus status, donor weight, donor height, donor hyperten-
sion, recipient–donor gender matching, and center volume. yRisk-adjusted for signif-
icant predictors of mortality in LAS era: serum creatinine, serum bilirubin, year of
transplantation, wait list duration, race, gender, mechanical ventilation before LTx,
ICU prior to LTx, bridging with ECMO, lung allocation score, recent infection, serum
cytomegalovirus status, dialysis while on wait list, blood transfusion while on wait
list, donor height, donor cytomegalovirus status, donor cigarette use, donor diabetes,
cytomegalovirus status match, and center volume.
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Solder elderly cohort in the LAS era and changes that
have been appreciated in the general LTx population such
as a greater percentage of patients with idiopathic pulmo-
nary fibrosis, a lower percentage of recipients with chronic
obstructive pulmonary disease, and shorter wait list
times.3,4
In addition to these changes, the rate of bilateral LTx in
septuagenarians was more than double in the modern cohort
than in the pre-LAS group, although this did not reach sta-
tistical significance. Several groups have demonstrated im-
proved survival in patients undergoing bilateral LTx
compared with single LTx for a variety of indications.5,6
This benefit seems less clear in older recipients, with
studies demonstrating conflicting results.7-10 Regardless, it
does appear from our analysis that more groups areFIGURE 2. Kaplan-Meier survival curves stratified by
1136 The Journal of Thoracic and Cardiovascular Surwilling to perform bilateral LTx in elderly patients,
although the vast majority continue to be single LTx.
ThemeanLAS in themodern cohort of septuagenarians in
our studywas 47.2, with 38% (74/195) of these patients hav-
ing an LAS greater than 46, corresponding to the greatest
quintile of risk in the general adult LTx population.11 There-
fore, the 1-year survival of 79.0% demonstrated in the pres-
ent cohort in the LAS era was acceptable. Furthermore,
although septuagenarians had increased risk-adjusted
mortality compared with a control cohort of recipients
aged 60 to 69 years in the pre-LAS era, we found no signif-
icant increase in 1-year mortality in septuagenarians under-
going LTx after implementation of the LAS.
Implications
The improvements in outcomes in septuagenarians
undergoing LTx are likely a reflection of clinical improve-
ments in transplant technique, postoperative care, and im-
munosuppression, among other factors. It is unclear from
our analysis to what degree the implementation of the
LAS system directly attributed to these improvements.
Nonetheless, it does appear from our data that outcomes
have substantially improved in recent years in this elderly
cohort of recipients. This has occurred despite more patients
with idiopathic pulmonary fibrosis, which represent a higher
risk subset and for which LTx offers a more limited survival
benefit than for other indications.12 Therefore, the collec-
tive data presented in our analysis are encouraging and sug-
gest that advanced age alone should not serve as an absolute
contraindication to LTx.
Although we adjusted for baseline differences between
groups, it is possible that improvements in patient selec-
tion in the elderly cohort could have contributed to the
better survival observed in the recent era. One favorablerecipient age and era. LAS, Lung allocation score.
gery c November 2012
Kilic et al General Thoracic Surgery
G
T
Sfactor in the recent septuagenarian cohort was a lower se-
rum creatinine compared with septuagenarians trans-
planted in the earlier era. Preoperative creatinine is
a known risk factor for developing renal failure requiring
dialysis postoperatively, a complication associated with
significant increases in mortality. A study of more than
12,000 LTx recipients confirmed the importance of preop-
erative renal function in determining postoperative renal
failure risk. Furthermore, they demonstrated a more than
sevenfold increase in 30-day and 1-year mortality and
more than fivefold increase in 5-year mortality in those de-
veloping renal failure after LTx compared with those who
did not.13
Another favorable factor noted in the more recent septu-
agenarian cohort was greater center volume. A study of
10,000 adult recipients found that centers with higher vol-
umes had the lowest short-term mortality rates after
LTx.14 Another nationwide analysis confirmed this associa-
tion between increasing center volume and decreasing
short-term mortality.15 Furthermore, it demonstrated that
this relationship has become more pronounced in recent
years.15 It is unclear from our analysis whether LTx in the
older population has been consolidated to high-volume cen-
ters in recent years or whether the higher center volume is
merely a reflection of more LTx procedures being per-
formed over time.
Previous Studies
Several previous studies have evaluated the effect of
older recipient age on outcomes after LTx. A single-
center review of 52 LTx patients aged 60 to 69 years dem-
onstrated comparable short- and long-term survival
compared with younger recipients.16 Another institutional
series of 32 LTx recipients aged 60 years or older also
demonstrated comparable survival, complication rates,
graft function, and frequency of bronchiolitis obliterans
syndrome compared with patients younger than 60 years
old.17 Similarly, a previous multicenter study by our group
focusing on predominantly pre-LAS patients found that
age older than 60 years was associated with comparable
30-day mortality compared with younger patients.18 Sep-
tuagenarians were at high risk of early mortality in that
previous analysis, similar to the pre-LAS cohort in our
present study, although our present study population added
an additional 168 septuagenarian recipients in the LAS era
and demonstrated significantly improved survival over
time.
Study Limitations
Similar to other multicenter registries, the UNOS data set
is susceptible to missing data entries and inaccurately
entered data. The registry is also limited to transplants
performed by centers within the United States. Although
some comorbidity data are available in the UNOS registry,The Journal of Thoracic and Cara validated index such as the Charlson or Deyo could not be
calculated for the present study but could be an important
measure, especially when discussing the physiologic versus
chronologic patient age. In addition, we limited our analysis
to the primary outcome of all-cause mortality, although
other outcomes, including quality of life, functional
capabilities, and resource usage are also important
measures, particularly in this patient cohort. We also did
not include long-term survival as an outcome measure, pri-
marily because the LAS cohort did not have sufficient
follow-up to conduct such analyses. In addition, it is unclear
from our analysis whether the implementation of the LAS
directly affected outcomes in elderly patients or whether
these merely reflect ongoing changes over time. Finally,
the present study was susceptible to type II error, although
a significant statistical difference was observed in the
smaller pre-LAS cohort, which was most susceptible to
this error. Furthermore, in the larger LAS era cohort, the ab-
solute difference in 1-year survival versus controls was very
small (1.0%), suggesting that the outcomes were likely
comparable in actuality and not just a limitation of sample
size.CONCLUSIONS
The present study is the largest to date examining out-
comes of LTx in septuagenarians. In this review of 225
LTx recipients aged 70 years or older, survival was compa-
rable to that of patients aged 60 to 69 years in the LAS
era, with significant improvements relative to pre-LAS sep-
tuagenarians. These data have collectively demonstrated
that with appropriate patient selection, favorable post-
transplant outcomes can be achieved in elderly recipients.
Therefore, advanced age should not serve as an absolute
contraindication to LTx in the present era.References
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